Background and purpose: Recent studies have elucidated that the bone marrow stromal cells (BMSCs) have therapeutic potential against stroke. Some clinical trials have been starting up in practice. We aimed to evolve the autologous BMSC transplantation for stroke into the next generation.
Materials and methods: Human BMSCs were cultured with human platelet lysate (hPL) instead of fetal calf serum (FCS). They were labeled with superparamagnetic iron oxide (SPIO). Rat ischemic stroke models were made and 5x105 cells were injected into the ipsilateral striatum stereotactically 7 days post-insult. Behavioral analysis, MRI for cell tracking, (18)F-FDG PET, and (123)I-Iomazenil SPECT were performed. The animals were sacrificed 5 to 8 weeks post-transplantation and histological analysis was performed.
Results: There was no difference in the surface markers and cell proliferation between hPL and FCS. Although rotarod test showed that motor function deteriorated in rats suffered from permanent MCAo, BMSC-hPL transplantation enhanced recovery of the motor function, significantly. MRI demonstrated that SPIO-BMSCs aggressively migrated towards the lesion. Moreover, (18)F-FDG PET and (123)I-Iomazenil SPECT showed that BMSC transplantation promoted recovery of the glucose utilization and the binding potential of iomazenil in the peri-infarct area, respectively. Histological analysis supported the findings on MRI and showed the inclination for neural differentiation of donor cells.
Conclusion: The hPL may be valuable and safe in expanding BMSCs. The application of bio-imaging techniques is also valuable for BMSC transplantation for stroke. Now we prepare the novel clinical trial against stroke, Research on Advanced Intervention using Novel Bone marrOW stem cell (RAINBOW) study. The present results are translated into the optimal design of the trial.